Wall Street analyst estimates for RenovoRx, Inc. (RNXT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Valuation Ratios
| Price / Book | 8.16 |
| EV / EBITDA | -8.01 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $43000 | $1.1M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $327000 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | $43000 | $796000 |
| Research & Development | $3.0M | $2.4M | $3.0M | $4.3M | $5.7M | $6.0M | $6.3M |
| Selling, General & Admin | $899000 | $818000 | $2.6M | $5.6M | $5.7M | $5.0M | $7.0M |
| Operating Expenses | $3.9M | $3.2M | $5.7M | $9.9M | $11.4M | $11.0M | $13.3M |
| Operating Income | -$3.9M | -$3.2M | -$5.7M | -$9.9M | -$11.4M | -$11.0M | -$12.5M |
| EBITDA | -$3.8M | 0 | -$5.5M | -$9.8M | -$10.1M | -$8.8M | -$11.2M |
| Interest Expense | 0 | $590000 | $904000 | $57000 | $108000 | 0 | 0 |
| Pre-tax Income | -$3.8M | -$3.8M | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$3.8M | -$3.8M | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
| EPS | $-0.22 | $-0.25 | $-0.40 | $-0.54 | $-0.50 | $-0.37 | $-0.32 |
| EPS (Diluted) | $-0.22 | $-0.25 | $-0.40 | $-0.54 | $-0.50 | $-0.37 | $-0.32 |
| Shares Outstanding (Diluted) | $17.3M | $17.3M | $17.9M | $18.1M | $20.6M | $23.6M | $35.3M |
Price
| Price | $1.55 |
| Market Cap | $70M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANVS · BCAB · CALC · CELU · ELUT · LTRN · MAIA
Explore sector: Healthcare · Biotechnology
More sections of RNXT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks